Though not defined by any one major breakthrough as in years past, the RNAi therapeutics field made steady progress in 2012, particularly in terms of product and technology development, according to industry insiders.

“2012 was really a year where the field built on the success of 2011 in keying up additional opportunities for clinical applications, and some novel delivery systems” that reflect the growing awareness of the issue of endosomal escape, Jeremy Caldwell, vice president of RNA Therapeutics at Merck, told Gene Silencing News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.